On November 16, at the 100th American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, US, results were ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

Findings from a 3-year analysis demonstrated that among patients treated with tirzepatide, 98.8% remained diabetes free.

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

Similarly, research from 2023 found that people who withdrew from tirzepatide regained a substantial amount of weight.

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...